Similarly, a phase III clinical trial conducted on patients with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutation, primary peritoneal cancer, and fallopian tube cancer reported that the overall incidence of anemia after the use of olaparib as maintenance therapy was 43%, whereas that of grade ≥3 anemia was 19% (3). This evidence concerns the gene BRCA1 and anemia (phenotype).